VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Mar 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-03-29

Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-29	Common Stock	M	13750	$73.51	Acquired	136261	Direct
2017-03-29	Common Stock	S	13750	$106.65	Disposed	122511	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-29	Stock Option (Right to Buy)	$73.51	M	13750	Disposed	2024-01-01	Common Stock (13750)	Direct

Footnotes

F1: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $106.65 (range $106.30 to $107.00).

F3: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: The option vests in 16 quarterly installments from 01/02/2014.